Dose–response effect of antibodies to S100 protein and cannabinoid receptor type 1 in released-active form in the light–dark test in mice
Earlier studies have shown that combination of antibodies to S100 protein and to cannabinoid receptor type 1 in released-active form (Brizantin) may possess anxiolytic properties and decrease nicotine dependence. Released-active form of antibodies is a novel approach that permits to modify natural functions of the target molecule (antigen) under investigation. The aim of the present study was to evaluate the anxiolytic-like effect of Brizantin in the light–dark test in mice, according to its ability to influence the number of entries into the lit compartment and the total time spent there. Three doses of Brizantin (2.5, 5, and 10 mL/kg) were compared with diazepam (1 mg/kg), placebo, and vehicle control. Anxiolytic-like effect of the tested drug was shown to be dose dependent, with an increasing trend from 2.5 to 10 mL/kg. Brizantin in its highest dose significantly increased studied behavioral parameters, although its effect was less pronounced than that of the reference drug diazepam (1 mg/kg).

Brizantin – new drug for treatment of nicotine addiction: results of multicenter clinical trial
Original title. Бризантин – новый препарат для лечения никотиновой зависимости: результаты многоцентрового клинического исследования

Author translation
Every year in the world, captured by global tobacco epidemic, 6 million people die because of smoking. Medical researches indicate connection of tobacco smoking with lung cancer, cardiovascular and many other diseases. Frequency of independent refusal of smoking at addicted people doesn't exceed 5%. In most cases they need the help of the doctor and pharmacological therapy to decrease a withdrawal implications. The fact of prescription of medicines (placebo effect) increases the frequency of smoking refusal to 10%. Effective drugs are antidepressants (bupropion), nicotine replacement products and partial agonists of nicotinic receptors (cytisinum, varenicline). However the use can be followed by side effects including nausea, rising of appetite, a headache, insomnia, a sleepiness, giddiness, a dysgeusia, vomiting, an inflation of the stomach and others. The new release-active drug for treatment of nicotine addiction Brizantin is created by the Materia Medika Holding company on the basis of antibodies to brain-specify protein S100 (anti-S100) and a cannabinoid-receptor of 1 type (anti-CB1). Clinical trials showed, antidepressive and anti-anxiety effects of the first component of anti-S100 can be compared by efficiency with amitriptyline, phenazepamum, sertraliny. The second component (anti-CB1) influences CB1-receptors hyper activation of which takes place at chronic smokers and also at persons people with obesity. Normalization of functional activity of the central and peripheric CB1-receptors reduces the need for intake of nicotine and also prevents rising of appetite and a set of weight among the people who left off smoking. Pilot studies proved synergetic anti-addictive effect of two components of Brizantin in their use.